a Instituto de Investigaciones Biomédicas en Retrovirus y Sida (INBIRS) , Universidad de Buenos Aires- CONICET , Buenos Aires , Argentina.
Expert Rev Anti Infect Ther. 2017 Aug;15(8):737-746. doi: 10.1080/14787210.2017.1354697. Epub 2017 Jul 17.
Hepatitis C virus (HCV) represents a major health concern, as nearly 3 million people become newly infected by this pathogen annually. The majority of infected individuals fail to clear the virus, and chronicity is established. Chronic HCV patients are at high risk for liver disease, ranging from mild fibrosis to cirrhosis and severe hepatocellular carcinoma. Over the last few years, the development of multiple direct acting antivirals (DAA) have revolutionized the HCV infection treatment, demonstrating cure rates higher than 90%, and showing less side effects than previous interferon-based regimens. Areas covered: Besides liver, HCV infection affects a variety of organs, therefore inducing diverse extrahepatic manifestations. This review covers clinical, experimental, and epidemiological publications regarding systemic manifestations of HCV, as well as recent studies focused on the effect of DAA in such conditions. Expert commentary: Though further research is needed; available data suggest that HCV eradication is often associated with the improvement of extrahepatic symptoms. Therefore, the emergence of DAA would offer the opportunity to treat both HCV infection and its systemic manifestations, requiring shorter treatment duration and driving minor adverse effects.
丙型肝炎病毒（HCV）是一个主要的健康关注点，因为每年有近 300 万人新感染这种病原体。大多数受感染的个体无法清除病毒，从而导致慢性感染。慢性 HCV 患者患肝病的风险很高，从轻度纤维化到肝硬化和严重的肝细胞癌不等。在过去几年中，多种直接作用抗病毒药物（DAA）的发展彻底改变了 HCV 感染的治疗方法，其治愈率高于 90%，并且副作用比以前基于干扰素的方案更少。涵盖领域：除了肝脏，HCV 感染还会影响多种器官，因此会引起多种肝外表现。这篇综述涵盖了关于 HCV 全身表现的临床、实验和流行病学出版物，以及最近集中研究 DAA 对这些病症影响的研究。专家评论：尽管需要进一步的研究，但现有数据表明，HCV 的清除通常与肝外症状的改善相关。因此，DAA 的出现将提供治疗 HCV 感染及其全身表现的机会，需要更短的治疗持续时间，并产生较小的不良反应。
